Truist Securities has initiated coverage on CG Oncology Inc (CGON) with a Buy rating as of November 23, 2025. This marks the firm's first assessment of the company, reflecting its evaluation of CG Oncology's investment potential amid the dynamics of the biotechnology sector.
Headquartered in Irvine, California, CG Oncology focuses on developing and commercializing bladder-sparing therapies for patients with bladder cancer. The company's lead product candidate, cretostimogene grenadenorepvec (cretostimogene), is currently in clinical development for non-muscle invasive bladder cancer (NMIBC). Notably, its BOND-003 trial is in Phase III, designed to evaluate the safety and efficacy of cretostimogene as a monotherapy for patients with high-risk BCG-unresponsive NMIBC.
As of November 20, 2025, CG Oncology boasts a market capitalization of $3.3 billion, with an earnings per share (EPS) of -1.76. Upcoming earnings are projected for August 6, 2026, with an estimated EPS of -0.72 and no expected revenue.
The consensus among analysts as of November 1, 2025, indicates a Buy rating, with 4 Strong Buy, 14 Buy, and 1 Hold among 19 total ratings. This update provides insight into CG Oncology's positioning within the biotechnology industry, especially as it navigates the complexities of clinical trials and market expectations.
Analyst ratings, such as this new Buy from Truist, serve as professional opinions based on extensive research and financial models. Investors should consider these assessments as part of a broader analysis that includes company fundamentals and industry trends, rather than the sole basis for investment decisions.